Weight loss during this period is often modest, perhaps 1 to 3 pounds, because the dose is below the threshold where all three receptors are fully engaged
Beyond T2D and weight management in individuals with overweight or obesity, GLP-1 receptor agonists are approved for metabolic dysfunction associated steatohepatitis in people with moderate or advanced fibrosis, obstructive sleep apnea in obese adults, reduction of major adverse cardiovascular events in adults with T2D and cardiovascular disease (CVD), and slowing progression of chronic kidney disease and cardiovascular mortality in adults with both chronic kidney disease and T2D
For many severe male infertility cases, this is one of the few viable routes
Patient Experiences and Testimonials With the evolving landscape of GLP-1 pricing and the potential for over-the-counter access, Im eager to share real-life experiences from patients whove incorporated these medications into their lives
For instance, nausea is common but usually transient